$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Biological Effect of Warfarin on Pancreatic Cancer

2019-05-15

2021-06

2022-06

0

Study Overview

Biological Effect of Warfarin on Pancreatic Cancer

This study aims to asses the effect of warfarin on markers of AXL pathway in patients with pancreatic adenocarcinoma.

There is emerging evidence from pre-clinical models that Axl activation is critical for the tumorigenesis and metastasis of pancreatic cancer. Warfarin is a readily available drug in the clinical setting and could be easily, safely, and quickly used in patients in combination with known cytotoxic chemotherapies to improve overall survival. Oral warfarin has been well tolerated in both prophylaxis for catheter-associated thrombosis and in advanced pancreatic cancer patients. The aim of this trial is to confirm the preclinical evidence that warfarin affects AXL pathway in patients with pancreatic cancer. This will validate the effect of escalating doses of warfarin on circulating biomarkers of AXL.

  • Pancreatic Cancer
  • DRUG: Warfarin
  • STU 022018-090

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2018-03-28  

N/A  

2021-03-23  

2018-05-14  

N/A  

2021-03-25  

2018-05-24  

N/A  

2021-03  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Warfarin

Patients will be assigned to warfarin by mouth daily on an outpatient basis. Dose level will increase after 5 patients enrolled. Dose 1 = 1 mg warfarin; Dose 2 = 2 mg warfarin; Dose 3 = 2.5 mg warfarin; Dose 4 = 4 mg warfarin and Dose 5 = 5 mg warfarin

DRUG: Warfarin

  • 5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Determine change in AXL pathwayDetermine change in circulating biomarkers of AXL pathways (including phosphogas6, soluble AXL).30 days
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Assess adverse eventsAssess the adverse events (per CTCAE v4.0 criteria) associated with the addition of warfarin in patients with pancreatic cancer receiving chemotherapy.30 days
Effect of warfarin on tissue markersEvaluate the effect of warfarin on tissue markers of the AXL pathways measured by western blot analysis in tumor tissue and expression levels of EMY markers following warfarin therapy.30 days
Antitumor effectAntitumor effects will be observed by change in CA9-19 levels pre and post warfarin. therapy.30 days

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Pathologically-confirmed, localized or metastatic adenocarcinoma of the pancreas. Diagnostic biopsy must be obtained at the study institution prior to enrollment. Pathology material must be available for review.
  • Patient must have measurable disease per RECIST criteria
  • Started most recent systemic therapy regimen within 15 days of enrollment (any line of therapy is allowed).
  • Ability to tolerate, swallow and absorb oral medications.
  • Ability to understand and the willingness to sign a written informed consent.
  • Age > 18 years
  • Negative blood pregnancy test within seven days of study entry for WOCBP
  • A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:


  • Has not undergone a hysterectomy or bilateral oophorectomy; or
  • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

    • Exclusion Criteria:

  • Active radiation therapy, or planned radiation therapy during study period
  • Subjects may not be receiving any other investigational agents.
  • Pregnant, nursing or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be potentially teratogenic.
  • Underlying condition which may increase the risk of complications from warfarin therapy. These can include:

    • Known major bleeding diathesis:

  • Coagulopathy
  • Significant GI bleed within 6 months,
  • Clinically significant hematuria or hemoptysis,
  • Thrombolytic therapy within one month of study entry,
  • Active peptic ulcer disease with bleeding. - Significant infection or other coexistent medical condition that would preclude protocol therapy including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • PRINCIPAL_INVESTIGATOR: Muhammad S Beg, MD, University of Texas Southwestern Medical Center

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    NPCF Pop up

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate